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Michael S. Conte, MD,a San Francisco, Calif; Denver, Colo; and New York, NY
Objective: Optimal selection of a revascularization strategy in femoropopliteal occlusive disease (FPOD) remains
controversial. Among endovascular treatment options for FPOD, covered stent placement has become increasingly used.
We sought to examine the influence of clinical, anatomic, and device-related characteristics on the clinical performance of
these devices.
Methods: This was a retrospective, single-center study of consecutively treated limbs that underwent Viabahn (W. L. Gore,
Flagstaff, Ariz) stent graft placement for FPOD from 2005 to 2010. Clinical, anatomic, and device-related characteristics
were obtained from review of medical records and angiograms. End points were occurrence of any reintervention, major
adverse limb event (eg, major amputation, thrombolysis/thrombectomy, or open bypass surgery), or thrombolysis/
thrombectomy treatment alone. Univariate predictors were calculated and multivariate models constructed for each
clinical end point using Cox proportional hazards models.
Results: The study cohort included 87 limbs in 77 unique patients, with a median follow-up time of 382 days. The
indication for intervention was claudication in 56%. In 25 cases (29%), the index procedure was a secondary intervention
for FPOD, including treatment of in-stent restenosis in 22 cases (25%). Lesions treated included 45% TransAtlantic
Inter-Society Consensus (TASC) II D and 58% chronic total occlusions. The observed Kaplan-Meier 1-year event rates for
reintervention, major adverse limb event (MALE), and thrombolysis were 43%, 28%, and 17%, respectively. MALE
occurred in 18 patients, nine of whom presented with acute limb ischemia; no patient underwent major amputation.
Univariate predictors of negative outcomes included lack of dual-antiplatelet usage, advanced TASC II classification,
smaller implant diameter, increased number of devices used, longer total implant length, and coverage of a patent distal
collateral vessel. Multivariate analysis demonstrated that the presence of dual-antiplatelet usage was protective against all
three outcomes, 5-mm device diameter was a risk factor for both reintervention and MALE, and the use of multiple
devices and distal collateral coverage were significant risk factors for thrombolysis events.
Conclusions: Reintervention is common in the first year after Viabahn placement for FPOD, with more than half of the
events being a MALE. Procedural factors such as antiplatelet therapy, stent graft diameter, implant length/number, and
distal collateral coverage are strongly associated with adverse clinical outcomes. These factors should be carefully
considered to optimize patient selection and intraoperative decision making for this procedure. (J Vasc Surg 2012;56:
998-1007.)
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MOptimal treatment of femoropopliteal occlusive disease
(FPOD) is controversial. Key factors to consider include
the severity of symptoms, comorbid conditions, anticipated
survival of the patient, and the anatomic pattern of disease.
Options for revascularization include angioplasty, atherec-
tomy, bare-metal stenting, covered stenting, or open by-
pass. The Viabahn stent graft (W. L. Gore, Flagstaff, Ariz)
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998s the most commonly used covered stent device in this
lass. Despite increasing utilization of covered stents in
POD, relatively little is known about the specific factors
hat influence outcomes in real-world practice and the
mpact of treatment failures on the patient.
Proponents of stent graft treatment for FPOD suggest
t compares favorably to open bypass with prosthetic,
hereby avoiding some of the attendant morbidities associ-
ted with that operation. Although angioplasty and/or
are-metal stenting are commonly used treatments for
POD, stent grafts have been promoted as advantageous
or longer, more severe lesions that are highly prone to
ndovascular treatment failure. As stent grafting represents
hybrid between angioplasty/stenting and prosthetic by-
ass, the specific risk factors and modes of treatment failure
or this procedure may be unique. We sought to investigate
hese factors by reviewing our institutional experience with
iabahn placement for the treatment of FPOD.
ETHODS
Study design. This was a single-institution retrospec-
ive study of a consecutive cohort of patients treated with
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Volume 56, Number 4 Johnston et al 999Viabahn stent grafts for FPOD. The University of Califor-
nia at San Francisco Institutional Review Board approved
the study. A list of patients was compiled from individual
surgeon case logs from January 1, 2005, to December 31,
2010. Patients were included only if a Viabahn device was
placed in the superficial femoral or popliteal artery for
chronic atherosclerotic limb ischemia. Patients with non-
atherosclerotic indications, such as aneurysm or trauma,
were excluded. Prior infra-inguinal covered stent place-
ment in the index limb was an exclusion criterion; other
prior endovascular or open interventions were permitted.
Medical chart review was used to compile baseline
characteristics, in-hospital complications, and subsequent
clinical events. Angiograms at the time of stent graft place-
ment and at subsequent clinical events were reviewed for
anatomic and device characteristics. Angiogram review was
done in a blinded fashion by a single individual (S.M.V.)
using the standardized definitions of lesions and collaterals
described below. The public Social Security Death Index
was searched for deaths not recorded in the University of
California at San Francisco record. Hospital financial re-
cords were queried for costs of the index procedure and
subsequent major adverse limb events (MALEs).
Stent graft placement technique. Percutaneous ac-
cess was gained from a contralateral or ipsilateral approach.
Preintervention angiography of the index limb was per-
formed. The lesion was crossed directly or subintimally if
required. Sizing was determined by preintervention imag-
ing or intravascular ultrasound scan (Volcano Corporation,
San Diego, Calif). Efforts were made to place the proximal
and distal graft landing zones in vessel areas relatively free of
atherosclerosis. The graft was deployed according to man-
ufacturer specifications and postdilated to implant size.
Care was taken not to aggressively balloon outside the graft
in the proximal and distal landing zones. Postimplantation
completion angiography was routinely performed.
Antiplatelet regimen. Patients were treated with a
dual regimen of aspirin (81 mg/d) and clopidogrel (75
mg/d) unless a specific contraindication was present. No
patient was started on warfarin therapy for this indication;
however, patients previously taking warfarin were main-
tained on warfarin in conjunction with a single antiplatelet
agent after the procedure. Triple therapy (aspirin, clopi-
dogrel, and warfarin) was not used. Antiplatelet therapy
was intended to be indefinite.
Follow-up. Patients were recommended to follow-up
with regular office visits, ankle-brachial index measure-
ments, and ultrasound scan examinations at 1, 3, and 6
months, then yearly thereafter. Compliance with postoper-
ative ultrasound scan was variable and, therefore, this study
was designed to focus on clinical events and not anatomic
patency.
Characteristics. The primary indication for stent graft
placement was recorded using the Rutherford class1 with
the definition of critical limb ischemia (CLI) being rest
pain, minor tissue loss, or gangrene. The number, length,
and size of implanted stent grafts were recorded. In calcu-
lating total implant length, we did not attempt to address she amount of overlap between devices, but rather used the
ummed length of the individual devices implanted. Our
nventory was updated to the heparin-bonded endograft
hen it became available in September 2007. The location
f the stent graft was defined as superficial femoral artery
nly, popliteal artery only, or combined. TransAtlantic
nter-Society Consensus (TASC) II definitions2 were as-
igned based on the pretreatment angiogram. The presence
f a chronic total occlusion (CTO) was defined as a com-
lete occlusion of any length. A redo procedure was defined
s any prior ipsilateral infrainguinal angioplasty, bare stent
lacement, or prior bypass. In-stent restenosis was defined
y narrowing within a prior uncovered stent in the femo-
opopliteal segment.
We examined the clinical significance of collateral artery
overage during stent graft placement by reviewing the
ngiograms and counting affected collateral pathways (Fig
). Proximal collaterals were defined as side branches off
he affected segment or upstream vessel flowing into the
urroundingmuscle tissue. Distal collaterals were defined as
ide branches coming in from the surrounding muscle to
upply blood to a downstream reconstituted segment. For
he purposes of analysis, proximal collateral coverage was
efined by coverage of five or more proximal collaterals by
he implanted devices (five was the median number of
roximal collaterals covered in the series). The variable
istal collateral coverage was defined as coverage of one or
ore distal collaterals by the implanted devices. Collateral
essels were counted if they seemed to be capable of accept-
ng the tip of a 0.014 wire, although this was not attempted
n practice. Runoff scores were calculated using the Society
or Vascular Surgery (SVS) four-level method.1
Events. Reintervention was defined as any subsequent
nfrainguinal endovascular or open procedure on the index
imb. Thrombolysis was defined as catheter-directed
hrombolysis or open thrombectomy of the treated seg-
ent as a result of stent graft thrombosis. Bypass was
efined as any open autogenous or prosthetic infrainguinal
r infrapopliteal bypass procedure. Major amputation was
efined as any amputation at the ankle level or above. A
ALE was defined as a composite of thrombolysis, open
ypass, or major amputation.3 Death was recorded as mor-
ality from any cause.
Clinical presentation upon failure. At the time of
eintervention, we recorded presenting signs and symp-
oms. Acute limb ischemia (ALI) was defined as an acute
hange in limb status with some degree of sensory or motor
hanges. All cases of ALI reported had evidence to place
hem in the Rutherford class IIa or greater category.1
Statistics. Outcome event rates were estimated using
aplan-Meier methods. Due to declining patient numbers,
e elected to close the dataset at 2 years postprocedure.
nivariate Cox proportional hazards models were con-
tructed for each predictor and scored according to the
ald test. Predictors were considered candidates for a
ultivariate Cox proportional hazard model if the Wald P
alue was .10 or less. A P value of  .05 was considered
ignificant. The standard error of the cumulative hazard
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October 20121000 Johnston et alwas calculated according to Greenwood’s formula. Calcu-
lations were performed with R 2.11.1 and Stata 11.2
(StataCorp LP, College Station, Tex).
RESULTS
Patient characteristics. Eighty-seven unique limbs in
78 patients satisfied the inclusion and exclusion criteria,
summarized in Table I. Mean and median follow-up was
477 days and 382 days, respectively (SD, 440; interquartile
range [IQR], 612). Indications for the procedure included
four (5%) for asymptomatic in-stent restenosis (ISR), 49
(56%) for claudication, and 34 (39%) for CLI (including
tissue loss in 25). In 25 cases (29%), Viabahn placement was
a secondary (redo) procedure after a previous infrainguinal
intervention. Eight patients (9%) were taking warfarin be-
fore and after device placement for other indications. After
the procedure, 85% were taking acetylsalicylic acid, 90%
were taking clopidogrel, 83% had dual-antiplatelet treat-
ment, and 70% were on statins. At least one postprocedural
surveillance ultrasound scan examination was noted in 55
of 87 cases (63%). Of these, 31 of 55 (56%) had more than
one study (range, 2-12); median time to first ultrasound
scan was 109 days.
Anatomic characteristics. Angiogram review re-
vealed that 61 (70%) were TASC II C or D lesions (Table
II). The majority of redo procedures were related to prior
uncovered stents in the femoropopliteal artery, all of which
were treated for ISR (22 cases, 25%). CTOs were present in
50 cases (58%).
To explore the relationship between coverage of alter-
nate circulatory pathways and clinical events, patent side
branches near the treated pathology were counted and
classified as described. Due to the variable quality of saved
angiographic images, this was not possible in nine cases. In
the remaining 78 cases, a median number of five proximal
Fig 1. Angiographic images of representative collaterals
the distal superficial femoral artery (SFA). B, Distal/in
artery.collaterals were covered (range, 0-16); 33 of 78 cases (42%) (nvolved coverage of five or more proximal collaterals.
here were fewer observed distal collaterals than proximal
ollaterals. In 44 of 78 cases (56%), no patent distal collat-
ral was covered, whereas in 35%, one distal collateral was
overed, and 9% of implantations covered two. Runoff
cores were calculated in 79 cases. Preserved three-vessel
unoff was observed in 23 cases (29%), whereas seven cases
roximal/outflow collaterals near a preocclusive lesion in
collaterals reconstituting the suprageniculate popliteal
able I. Patient characteristics
haracteristic Proportion
edian age (minimum, maximum, IQR) 69 (47, 98, 18.5)
emale gender 28 (32%)
ypertension 74 (85%)
yslipidemia 65 (75%)
iabetes 43 (49%)
oronary artery disease 42 (48%)
ongestive heart failure 13 (15%)
troke 10 (12%)
enal failure 5 (6%)
obacco use (ever) 78 (89%)
ctive smoking 26 (30%)
ostoperative medications
tatin use 61 (70%)
spirin use 74 (85%)
lopidogrel use 78 (90%)
ual-antiplatelet use 72 (83%)
arfarin use 8 (9%)
ndications
Asymptomatic (ISR) 4 (5%)
Claudication 49 (56%)
LI 34 (39%)
Rest pain 9 (10%)
Ulceration 13 (15%)
Gangrene 12 (14%)
edo procedure 25 (29%)
LI,Critical limb ischemia; IQR, interquartile range; ISR, in-stent restenosis.
roportion of patients for each index procedure (n  87 unique limbs) are
iven unless a different statistic is stated (minimum, maximum, IQR)..A, P
flow9%) had at least a 50% stenosis in all three tibial vessels.
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Volume 56, Number 4 Johnston et al 1001Device characteristics. The median number of de-
vices used was two (range, 1-4 devices; Table III). The
median sum length of implanted devices was 300 mm
(range, 25 mm-600 mm). The minimum size used was 5
Table II. Anatomic characteristics
Characteristic Proportion
Location
Superficial femoral only 38/87 (44%)
Femoropopliteal 43/87 (49%)
Popliteal only 6/87 (7%)
Runoff score
0 23/79 (29%)
1 25/79 (32%)
2 24/79 (30%)
3 7/79 (9%)
Lesions
ISR 22/87 (25%)
CTO 50/87 (58%)
TASC II classification
A 14/87 (16%)
B 12/87 (14%)
C 22/87 (25%)
D 39/87 (45%)
Collaterals
Proximal collateral coverage (five or
more)
33/78 (42%)
Median proximal collateral coverage
(minimum, maximum, IQR)
5 (0, 16, 4)
Distal collateral coverage:
0 44/78 (56%)
1 27/78 (35%)
2 7/78 (9%)
Distal collateral coverage (one or more) 34/78 (44%)
CTO, Chronic total occlusion; IQR, interquartile range; ISR, in-stent
restenosis; TASC, TransAtlantic Inter-Society Consensus.
Proportion of patients for each index procedure (n  87 unique limbs) is
given, unless a different statistic is stated (minimum, maximum, IQR). Due
to the variable quality of saved angiographic images, collateral data were
available in only 78 of 87 (90%) of procedures; runoff data were available in
79 of 87 (91%). Runoff score is the Society for Vascular Surgery (SVS)
four-level grading method.
Table III. Device-related characteristics
Characteristic Proportion
Minimum device size
5 mm 24 (28%)
6 mm 61 (70%)
7 mm 2 (2%)
Number of stent grafts
1 29 (33%)
2 26 (30%)
3 27 (31%)
4 5 (6%)
Heparin-bonded stent graft 73 (84%)
Median summed length, in cm (minimum,
maximum, IQR)
300 (25, 600, 200)
Total length 20 cm 31 (36%)
IQR, Interquartile range.
Proportion of patients for each index procedure (n  87 unique limbs) is
given unless a different statistic is stated (minimum, maximum, IQR).mm in 24 cases (28%), 6 mm in 61 cases (70%), and 7 mm sn two cases (2%). In 73 of cases (84%), heparin-bonded
rafts were used.
Significant associations between baseline variables.
emale gender (P  .001; 2 test) and treatment of CLI
P .001; 2 test) were strongly associated with the use of
-mm devices. The use of multiple devices and longer
mplant length was positively correlated with TASC II
cores. Proximal collateral coverage was associated with the
se of multiple stent grafts and longer implant length.
Summary of overall outcomes. There was no in-
ospital mortality with the index procedure. In-hospital
orbidity was observed in seven of 87 patients (8%), in-
luding urinary tract infection (n  1), acute renal failure
n  2), congestive heart failure (n  1), atrial fibrillation
n  1), non-ST elevation myocardial infarction (n  1),
nd access-site infection (n 1). The median length of stay
or the index procedure was 1 day (range, 1-21 days).
ne-year event rates for the study cohort (Table IV) were
eath 17%, major amputation 0%, reintervention 43%,
ALE 28%, and thrombolysis in 17% (Fig 2).
Reintervention events. There were 26 primary rein-
ervention events, including angioplasty  stenting
seven), additional covered stent placement (five), throm-
olysis (seven), thrombectomy (one), and open bypass
six). Univariate predictors are summarized in Table V. The
se of dual-antiplatelet therapy had a protective association
hazard ratio [HR], 0.41; P  .060). The use of 5-mm
evices was associated with a greater need for reinterven-
ion with an HR of 2.25 (P  .046). There was a trend of
ncreased risk with higher levels of lesion severity (TASC C
nd D) having an HR of 1.6 (P  .065). Notably, patients
ith claudication were equally likely to require a reinter-
ention as those with CLI. Among the anatomic variables,
resence of CTO, native disease vs ISR, runoff score, and
ollateral vessel coverage did not correlate with reinterven-
ion.
MALEs. There were 18 primary MALEs summarized
n the Appendix (online only). In two cases, thrombolysis
as followed immediately by lower extremity bypass for a
otal of 20 MALEs in 18 unique limbs. MALE occurred in
9% of claudicants and 24% of patients with CLI (PNS).
he events consisted of 10 thrombolysis episodes and eight
ower extremity bypasses; no major amputations occurred.
ospitalizations for treatment of MALE were associated
ith 0% mortality, 30% morbidity, and a mean length of
able IV. One-year outcomes for overall cohort
utcome Event rate 95% CI SE
eath 17% 7%-26% 0.047
eintervention 43% 28%-54% 0.067
ALE 28% 16%-39% 0.060
hrombolysis 17% 6%-25% 0.049
I, Confidence interval; MALE, major adverse limb event; SE, standard
rror.
hrombolysis  catheter-directed thrombolysis or open thrombectomy.tay of 6 days (range, 1-31 days).
JOURNAL OF VASCULAR SURGERY
October 20121002 Johnston et alFig 2. Kaplan-Meier time-to-event plots of the overall cohort for reintervention, major adverse limb event (MALE),
and thrombolysis end points. The standard error is 10% for all time points other than reintervention beyond 1 year.Table V. Univariate associations with clinical end points (Wald test P values)
Reintervention
HR (95% CI); P value
MALE
HR (95% CI); P value
Thrombolysis
HR (95% CI); P value
Patient characteristics
Female gender 1.76 (.81-3.81); .155 2.04 (.81-5.15); .133 1.23 (.35-4.37); .747
Diabetes 1.12 (.52-2.41); .777 1.13 (.45-2.84); .801 .73 (.21-2.58); .621
CAD 1.05 (.49-2.28); .894 .92 (.36-2.34); .864 1.19 (.35-4.13); .780
Statin use .89 (.38-2.13); .800 .69 (.26-1.84); .459 .92 (.24-3.56); .900
Dual-antiplatelet therapy .41 (.17-1.04); .060 .27 (.10-.73); .009 .13 (.04-.46); .001
CLI 1.34 (.60-3.02); .479 2.14 (.84-5.45); .111 .99 (.25-3.84); .990
Anatomic characteristics
TASC A  B, C, D 1.60 (.97-2.63); .065 2.00 (1.03-3.88); .040 2.81 (.96-8.16); .058
CTO 1.17 (.53-2.57); .703 1.12 (.44-2.90); .811 1.65 (.43-6.38); .469
ISR 1.31 (.57-3.01); .529 1.42 (.53-3.80); .480 1.27 (.33-4.91); .730
Poor runoff 0.922 (.40-2.20); .874 1.91 (0.71-5.12); .200 1.28 (.34-4.79); .711
Proximal collateral coverage 1.87 (.81-4.32); .146 2.01 (.73-5.54); .176 4.06 (.84-19.50); .081
Distal collateral coverage .87 (.38-1.99); .740 1.22 (.46-3.26); .688 4.43 (.92-21.30); .064
Device characteristics
Minimum diameter 5 mm 2.25 (1.02-4.98); .046 2.31 (.89-5.98); .084 1.34 (.35-5.18); .674
Heparin-bonded stent graft .62 (.27-1.42); .255 1.03 (.34-3.13); .962 .62 (.16-2.39); .487
Total length 20 cm 1.03 (.46-2.31); .943 .35 (.10-1.23); .101 No events. 003a
More than one stent graft .96 (.42-2.22); .931 2.39 (.69-8.27); .169 No events. 006a
Number of stents 1.08 (.71-1.65); .717 1.81 (1.07-3.05); .027 2.24 (1.10-4.55); .026
CAD, Coronary artery disease; CI, confidence interval; CLI, critical limb ischemia; CTO, chronic total occlusion; HR, hazard ratio; ISR, in-stent restenosis;
TASC, TransAtlantic Inter-Society Consensus.
Poor runoff defined as Society for Vascular Surgery (SVS) modified runoff score 2 or 3.
aUnable to compute HR and Wald test P value due to lack of events in the reference group; in these two cases, the likelihood ratio test is reported.
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Volume 56, Number 4 Johnston et al 1003Univariate predictors of time to MALEs are summa-
rized in Table V. Dual-antiplatelet therapy had a significant
protective association (HR, 0.27; confidence interval [CI],
0.10-0.73; P  .009). Increasing disease severity (TASC
A  B vs C vs D; HR, 2.00; CI, 1.03-3.88; P  .040) and
number of stent grafts used (HR, 1.81 per additional device
beyond the first; CI, 1.07-3.05; P  .027) were associated
with MALE. Minimum implant diameter of 5 mm was also
associated with MALE (HR, 2.31; CI, 0.89-5.98; P 
.084).
Thrombolysis. There were 10 thrombolysis events in
10 unique limbs, two of which were secondary reinterven-
tions. Thrombolysis occurred in four of 34 patients (12%)
with CLI and six of 49 (12%) with claudication. No throm-
bolysis events were observed in cases where only one
Viabahn device had been placed, or when the summed
length of implanted devices was 20 cm. The use of dual-
antiplatelet therapy had a strong protective association
(HR, 0.13; P  .003). Coverage of at least one distal
collateral was associated with the need for thrombolysis with
an HR of 4.43 (P  .064), as was TASC classification (HR,
2.81; P .058).
Thrombolysis was successful in clearing the occlusion
in eight of 10 cases; in all, a stenosis at one or both ends of
the stent graft was treated. In-hospital care associated with
the thrombolytic episodes was associated with nomortality,
20% morbidity, and a mean length of stay of 3.5 days
(range, 1-21 days).
ALI. Nine patients presented with ALI in the index
limb during follow-up, six of whom were originally claudi-
cants. Univariate predictors of ALI were total implant
length20 cm (P .05) and coverage of at least one distal
collateral (P  .05). Patients having an initial indication of
claudication vs CLI were equally likely to develop ALI (P
.99).
Multivariate predictors. Cox proportional hazards
models are summarized in Table VI. For reintervention,
significant independent predictors included dual-antiplatelet
therapy and 5-mm graft diameter (P  .027 and .036,
respectively; Fig 3). For MALE, dual-antiplatelet therapy,
5-mm graft diameter, and number of grafts used were
important independent predictors (P  .007, .053, and
Table VI. Multivariable model for clinical end points (Co
Outcome Characteristic
Reintervention Dual-antiplatelet therapy
TASC II A, B, C, D
Minimum diameter 5 mm
MALE Dual-antiplatelet therapy
Number of devices used
TASC II A, B, C, D
Minimum diameter 5 mm
Thrombolysis Dual-antiplatelet therapy
TASC II A, B, C, D
Distal collateral coverage
CI, Confidence interval; HR, hazard ratio; TASC, TransAtlantic Inter-Soci.064, respectively; Fig 4). For thrombolysis, dual-antiplatelet bherapy and distal collateral coverage were independently
redictive (P  .003 and .020, respectively; Fig 5).
Cost. Cost data for the index hospitalization were
vailable in 83 cases (95%). Mean direct costs (including
mplant cost, operating room use, drugs, laboratory tests,
tc) were US $18,818 (range, $5,413-$64,496); implant-
elated costs accounted for $7,712 (range, $2,461-
20,307) of this. The mean direct cost associated with
ALEs was $25,593 (range, $9,050-$84,675). This was
omparable to thrombolysis-related hospitalizations with a
ean cost of $27,665 (range, $15,808-$39,718).
ISCUSSION
In this single-institution series of Viabahn placement
or FPOD, we observed a significant number of clinical
vents within the first year. Reintervention was required in
ore than 40% of patients within the first year, with more
han half of these events being a MALE (ie, open bypass or
hrombolysis). This series consists of a heterogeneous and
natomically challenging population, including a substan-
ial percentage of secondary procedures (29%), ISR pathol-
gy (25%), CLI (39%), and TASC C/D lesions (70%).
owever, these are subgroups of greatest potential interest
or this technology, and, therefore, the outcomes and pre-
ictors we observed are noteworthy. Poor compliance with
ltrasound scan surveillance in our cohort renders us un-
ble to comment on anatomic patency and may also have
ontributed to the frequency and magnitude of the events
bserved. Although there are important limitations to the
nalysis of this modest-sized cohort, our data suggest that
ey anatomic and periprocedural factors are strongly asso-
iated with the outcomes of this procedure and should
nfluence clinical decision making.
Reintervention andMALE are clinically important out-
ome measures recently endorsed by the SVS working
roup in CLI that differ from classically reported patency
ates. Data from the SVS Objective Performance Goals
OPG) project, comprised of adjudicated trial data from
LI-only multicenter studies, suggest that the incidence of
ALE observed here is similar to that seen after endovas-
ular intervention for CLI (freedom from MALE at 1 year
1.7% [66.1-77.3]) and higher than observed for vein
portional hazards, univariate entry criteria P  .10)
HR 95% CI P value
0.34 0.13-0.88 .027
1.52 0.92-2.51 .103
2.43 1.06-5.57 .036
0.23 0.08-0.67 .007
1.66 0.97-2.84 .064
1.72 0.86-3.41 .121
2.66 0.99-7.17 .053
0.10 0.02-0.46 .003
2.10 0.72-6.15 .177
7.96 1.44-45.4 .020
nsensus.x proypass surgery in CLI (78.5% [75.6-81.4]; open access data
a
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present cohort were claudicants. Notably, none of the
MALEs in this series was a major amputation.
Due to lack of accurate data on anatomic patency, as well
as important differences in the study populations, it is difficult
to directly compare our results with the published reports of
endograft treatment for FPOD. The Viabahn versus bare
nitinol stent (VIBRANT) trialists4 (NCT00228384) ran-
domized 148 patients to Viabahn vs bare nitinol stenting for
superficial femoral artery (SFA) occlusive disease. The investi-
gators have presented their 3-year results (VIVA 2011), but
publication of the complete study outcomes is still awaited.5
Fig 3. Kaplan-Meier time-to-event plots for the reinter
model (Table VI) with corresponding P values are show
dual-antiplatelet therapy. B, Freedom from reinterventi
Freedom from reintervention stratified by TransAtlantic I
point where the standard error is 10%.
Fig 4. Kaplan-Meier time-to-event plots for the major
included in the final multivariable model (Table VI) with
stratified by the presence of dual-antiplatelet therapy. B
diameter of 5 mm. C, Freedom from MALE stratified b
standard error is 10%.There was no significant difference between the two study srms of VIBRANT in the primary efficacy outcomes at 1 year.
he 1-year occlusion rate of nine of 72 (13%) is similar to the
ate of thrombolysis we observed (17%).
Other groups have reported variable success. Alimi et
l6 reported 1-year primary and secondary patency rates of
4% and 84%, including 21% Viabahn occlusions at 10
onths. Verta et al7 described results in 28 cases of subin-
imal recanalization of anatomically advanced TASC II
esions (64% TASC D); 43% failed at 8 months, most in the
orm of edge stenoses. McQuade et al8 performed a ran-
omized controlled trial comparing Viabahn stent grafting
o open surgery, demonstrating equivalent primary and
n end point. Factors included in the final multivariable
, Freedom from reintervention stratified by presence of
ratified by minimum stent graft diameter of 5 mm. C,
Society Consensus (TASC) II (A B vs C vs D). *Time
se limb event (MALE) end point. The top three factors
sponding P values are shown. A, Freedom fromMALE
eedom from MALE stratified by minimum stent graft
use of more than one device. *Time point where theventio
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Volume 56, Number 4 Johnston et al 1005knee bypass. Of the 50 stent grafts implanted, 17 (34%)
occluded at a mean time of 8 months. Lepantolo et al9
conducted a similar trial in Europe, which was stopped early
due to the significantly inferior 1-year primary patency rate
of the endograft arm (46% vs 85%; n  44). Other peer-
reviewed references cited in the Viabahn for SFA product
literature focus on outcomes of patency alone with limited
or absent description of clinical events.6,8,10-15 Two ongo-
ing studies of the Viabahn device in femoropopliteal occlu-
sive disease include the VIPER16 and VIASTAR17 trials. To
address issues of edge stenosis, a newer device with a
proximal contoured edge has been designed and is the
focus of a nonrandomized postmarket approval study
(VIPER, NCT00541307).16 The VIASTAR trial (IS-
RCTN48164244) is a European study randomizing pa-
tients with 15-cm SFA lesions to bare nitinol stents or
covered Viabahn grafts.17
In our experience, the characteristics that influence
clinical failure after Viabahn treatment are related to anat-
omy, device and technical considerations, and postopera-
tive management. Surprisingly few patient-level factors had
any notable associations with the clinical outcomes. The
indication for treatment – claudication vs CLI – was not
associated with midterm clinical outcomes in this study.
This is likely a result of patient selection, modest numbers,
and limited follow-up time but also reflects the significant
adverse event rate we observed in claudicants. Female gen-
der was weakly associated with the use of smaller-diameter
implants and need for reintervention. An important finding
is the strong association observed between dual-antiplatelet
therapy and outcomes. These data suggest that patient
selection should consider the ability to tolerate aggressive
antiplatelet therapy, and postoperative medication compli-
ance should be stressed. We cannot comment on the utility
of anticoagulant therapy or specific combinations of anti-
Fig 5. Kaplan-Meier time-to-event plots for the throm
multivariable model (Table VI) with corresponding P va
presence of dual-antiplatelet therapy. B, Freedom from th
C, Freedom from thrombolysis stratified by the use of Tran
*Time point where the standard error is10%.platelet and anticoagulant medications in this series. tAnatomic determinants influence distinct failure modes
f Viabahn, bare metal stenting, and conventional bypass
urgery. Disease severity (TASC) is an important factor in
iabahn outcomes; however, the size of the treated artery is
t least equally so. The presence of either CTO or ISR were
ot discriminating factors. This suggests that these devices
ay be effective in excluding previously occluded and/or
tented regions but then remain subject to edge stenosis
nd subsequent stent graft occlusion.
Other key device-related factors, including implant di-
meter, total implant length, number of stents deployed,
nd collateral vessel coverage are correlated with anatomic
onstraints but may also reflect procedural choices. Despite
ASC class, there is evidence here to suggest that adding
dditional devices or extending device length may predis-
ose the limb toward a major adverse event. This study
rovides provocative data that coverage of visible distal
ollaterals in downstream reconstituted segments may pre-
ispose patients to an increased risk of subsequent throm-
osis with clinical deterioration. We are not able to discern
hether extension of the treatment zone to cover mild or
oderate disease, as advocated by some practitioners, is
ither a risk or a benefit. However, the results we observed
uggest such intraoperative decisions should be carefully
ade despite the potential improvement in immediate
echnical appearance.
The incidence of ALI and use of thrombolysis observed
n this series is notable, particularly the events that occurred
n patients initially treated for claudication. This issue may
e intertwined with the role of ultrasound scan surveillance
nd prophylactic reintervention to avoid endograft throm-
osis. Further studies are needed to better define the risk
ssociated with collateral vessel coverage and the effective-
ess of surveillance after this procedure.
Limitations. This study was limited by its retrospec-
is end point. The top three factors included in the final
are shown. A, Freedom from thrombolysis stratified by
olysis stratified by coverage of at least one distal collateral.
tic Inter-Society Consensus (TASC) II (A B vs C vs D).bolys
lues
romb
sAtlanive nature, modest size, follow-up duration, and variable
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that some events not captured here could have altered the
statistical conclusions. As 10 patients had both limbs en-
rolled in this cohort, nonindependence of the patient and at
least some of the anatomic characteristics could have af-
fected the statistical conclusions. The total implant length
variable was chosen to encapsulate both disease severity and
intraoperative decision making, which differs from length
of the treated segment. Due to a lack of uniform use of
angiographic distance markers in this series, lesion length
was not available for analysis.
CONCLUSIONS
Reintervention rates following Viabahn treatment for
FPOD were40% within the first year, and more than half
of the observed clinical events were MALE. TASC D le-
sions, small-diameter (5 mm) devices, number and
summed length of devices implanted, and distal collateral
coverage are adverse factors to be carefully considered in
patient selection and intraoperative decision making. Our
results suggest particular caution in the treatment of clau-
dicants who have multiple unfavorable anatomic character-
istics for stent grafts as outlined herein. The importance of
dual-antiplatelet therapy after Viabahn graft placement
seems paramount. Further studies are needed to clarify the
clinical effectiveness of covered stents in the treatment of
FPOD; however, our results provide insights to guide the
application of this technology until higher-quality data are
available.
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Dr Gregory L. Moneta (Portland Ore). This study is retro-
spective, so we expect some data to be missing. Some deficiencies
are expected and, to the author’s credit, acknowledged. However,
there are some very basic data missing. We really don’t know howion. Follow-up is best described as inconsistent and the authors
ould not provide quantitative information on patency; although
y implication, patency was poor. There is no information on
uality of life. There is no cost information with respect to the
nitial procedure. We don’t know if wounds healed or walking
mproved. The data do not allow us to be convinced the patients
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old fashioned vein bypass! Overall, we get the impression the
procedures were performed without careful ongoing assessment of
results similar to those cardiologists and interventional radiologists
we were all so critical of 15 years ago. As they say, “we have looked
at the enemy and he is us!” On a more serious note, in my opinion,
evaluation of a new procedure in one’s practice requires a height-
ened level of vigilance that seems to be lacking here.
What has this study confirmed? It confirms Willard Johnson’s
data from, I believe, the early 90s, that smaller-caliber prosthetic
grafts for treatment of femoral popliteal occlusive disease do not do
well. Category: “Wheel: reinvention of”! It certainly confirms my
bias that prosthetic devices of any sort for infrainguinal occlusive
disease remain suboptimal and best avoided if possible. The study
does confirm these devices can be reliably placed with a high
technical success rate, although one would have to ask with the
data presented, why you would want to?
We have confirmed that the Rutherford classification of limb
ischemia needs to be seriously reassessed. No so-called critically
ischemic limb in this series ended up with an amputation despite
all the graft failures. Perhaps these were not necessarily all that
critically ischemic limbs? Finally, we have basically confirmed
there is no free lunch in vascular surgery. Even in the endovas-
cular era, failure still comes with a price and a really good
small-caliber arterial substitute remains the Holy Grail of vas-
cular surgery.
However, we have learned a few things; some good, some bad.
We have learned, with a little effort, we can apparently change the
natural history of the limb in patients with claudication to be
similar to that of the natural history of the limb in patients with
critical limb ischemia. That is not a good thing. We have learned
engineers continue to be smarter than biochemists. Engineers
can design clever devices, but the biochemists still have not
figured out how to stop the intimal hyperplasia induced by these
clever devices. Endovascular therapy for infrainguinal occlusive
disease is going to get better. Despite all the marketing, how-
ever, real improvement will not occur until the biochemists
catch up with the engineers.
What is good? The paper is well written. The author’s obser-
vations on implant length/number and diameter, on coverage of
collateral vessels and the potential utility of dual-antiplatelet ther-
apy are of real importance and should be taken seriously by anyoneishing to implant these devices. The analysis of the data that is
vailable is honest and first rate.
I have a few questions:
. Is there still enthusiasm for this procedure at UCSF?
. There are some longer term risks with dual-antiplatelet therapy.
What proportion of peripheral arterial disease patients can
tolerate aspirin and clopidogrel long term? Have you any sug-
gestion as to when to stop dual-antiplatelet therapy, if ever?
. Would you use a good arm vein over this stent graft in a patient
with critical limb ischemia?
. Follow-up is a problem for anyone doing clinical research,
especially retrospective clinical research. What are you doing to
improve follow-up in your patients? Dr Johnston now works at
Kaiser in Denver. I look to Kaiser to help us with preventative
medicine. Do you do anything different at Kaiser with respect
to patient follow-up than was done at UCSF?
Dr Paul C. Johnston.DrMoneta, thank you for your honest
nd critical appraisal.
. I would have to confirm that, yes, enthusiasm for this pro-
cedure has waned at UCSF. After we started seeing some of
these patients come back with acute limb ischemia, red flags
started going up, and that was the impetus for starting this
project. Once the data were collected and analyzed, it further
changed our perspective.
. This is an unanswered question. Although we have anecdotally
not seen major bleeding complications with dual-antiplatelet
therapy, this study was not designed to capture all bleeding
events that may have occurred outside of our direct care. There is
no clear time point based on our data when the appropriate time
point to stop dual-antiplatelet therapymay be. As a result, we have
kept patients on both agents unless a contraindication arises.
. Therapy has to be individually tailored. In a patient with a
reasonable life expectancy and the ability to tolerate a poten-
tially lengthy procedure under general anesthesia, arm vein is a
good option.
. At Kaiser, we do benefit from a more closed system than exists at
many university hospitals such as UCSF. The electronic medical
record and finite set of care providers facilitates ongoing follow-up
both in terms of in-person office visits and surveillance studies.We
are also taking coordinated steps toward establishing surveillance
protocols andpatient registries for all permanent implants. There is
an unmet need to establish registry databases that we can all use to
better track patient outcomes.
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No. R/T Days Event, symptoms Treatment
1 6/C 9 Occlusion, ALI SFA-PT bypass
2 3/D 27 Occlusion, ALI CFA TEA, thrombectomy, additional Viabahn
3 4/D 50 Occlusion, recurrent rest pain SFA-peroneal bypass
4 0/D 69 Occlusion, recurrent rest pain Thrombolysis, PTA, atherectomy
5 3/D 93 Occlusion, recurrent rest pain Thrombolysis, additional Viabahns
6 5/D 94 Occlusion, ALI Thrombolysis, additional Viabahn
7 6/A 97 Patent, persistent gangrene IGP-DP bypass
8 5/D 100 Occlusion, ALI Thrombolysis, additional stent
9 4/D 105 Occlusion, recurrent rest pain Thrombolysis, additional stent
10 3/D 132 Occlusion, ALI Thrombolysis, CFA-AT bypass, fasciotomy
11 3/D 149 Occlusion, ALI Thrombolysis, additional stent
12 3/C 171 Occlusion, recurrent claudication Femoral reconstruction, thrombectomy, additional stent
13 3/D 215 Occlusion, ALI Thrombolysis, additional stent
14 3/C 259 Occlusion, recurrent claudication CFA-IGP bypass
15 4/D 273 Occlusion, recurrent rest pain CFA-PT bypass
16 6/D 282 Occlusion, recurrent ulceration SFA-IGP bypass
17 3/A 349 Occlusion, ALI Thrombolysis, tibial embolectomy, CFA-IGP bypass
18 3/D 505 Occlusion, ALI CFA-IGP bypass
ALI, Acute limb ischemia; AT, anterior tibial; CFA, common femoral artery; DP, dorsalis pedis; IGP, infrageniculate popliteal artery; MALE, major adverse
limb event; PT, posterior tibial; PTA, percutaneous transluminal angioplasty; SFA, superficial femoral artery; TASC, TransAtlantic Intersociety Consensus;
TEA, thromboendarterectomy.
R/T indicates clinical indication (Rutherford class) and TASC II class of the index procedure. Days indicates time to failure relative to the index procedure.
Event describes the first method of failure and symptoms associated with stent graft failure. Treatment describes the interventions performed in response of
failure.
